Full Press Release Details
Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal
Foralumab in Alzheimer's Disease
NEW YORK, August 17, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq:
TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies
via novel routes of drug delivery, today announced that Dr. Howard L. Weiner, a thought leader in the field of neurology and immunology,
was featured in an exclusive live interview on Bloomberg to discuss the Company's latest announcement on its advancement of the
novel foralumab program in Alzheimer's disease following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)
clearance. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
During the live interview, Professor Howard L. Weiner, a distinguished
expert in neurology and immunology and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital,
a founding member of Mass General Brigham Healthcare System, discussed Tiziana's planned clinical program in Alzheimer's disease
and the potential for foralumab in treating inflammation across multiple neurological conditions. Dr. Weiner is the Chairman of Tiziana's
Scientific Advisory Board and his deep expertise and experience places him in a unique position to provide valuable insights into the
potential impact of Tiziana's technology.
"Alzheimer's disease, a difficult-to-treat neurodegenerative
disorder affecting millions worldwide, represents a significant unmet need and has long been a challenge in medical research" stated
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. "Tiziana's commitment to innovation has driven us to
explore novel solutions to this complex condition via intranasal foralumab, that, in previous studies, has been shown to modulate and
dampen neuroinflammation. Dr. Weiner's discussion on Bloomberg offers a glimpse into the potential game-changing solutions in neuroinflammation
that Tiziana is pursuing, not only in Alzheimer's but also in our upcoming Phase 2 trial in non-active secondary progressive multiple
sclerosis which will begin shortly this year."
The interview can be found via this link:
Activated T cells play an important role
in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens
inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been
demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials
are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents
a novel avenue for treatment of inflammatory human diseases.1
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety
and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully
human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's
technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad
pipeline applications.
Forward-Looking Statements
Certain statements made in this announcement
are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,' intends,'
plans,' believes,' seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These statements
are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted
in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance
on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake
any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC